December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Gene Therapy for Retinoblastoma: Report of a Pilot Clinical Study
Author Affiliations & Notes
  • P Chevez-Barrios
    Baylor College of Medicine Houston TX
  • M Chintagumpala
    Baylor College of Medicine Houston TX
  • M Boniuk
    Baylor College of Medicine Houston TX
  • MY Hurwitz
    Texas Children's Cancer Center
    Baylor College of Medicine Houston TX
  • RL Hurwitz
    Center for Cell and Gene Therapy
    Baylor College of Medicine Houston TX
  • Footnotes
    Commercial Relationships   P. Chevez-Barrios, None; M. Chintagumpala, None; M. Boniuk, None; M.Y. Hurwitz, None; R.L. Hurwitz, None. Grant Identification: Foundation for Research
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2895. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      P Chevez-Barrios, M Chintagumpala, M Boniuk, MY Hurwitz, RL Hurwitz; Gene Therapy for Retinoblastoma: Report of a Pilot Clinical Study . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2895.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To test the safety and possible efficacy of using intravitreal and intratumoral injections of adenoviral vectors to deliver the herpes thymidine kinase gene (AdV/TK) followed by ganciclovir to treat refractory retinoblastoma in children. Methods: A RAC, IRB, and FDA approved phase I intra-patient dose-escalation clinical trial was established. Patient eligibility was restricted to children with bilateral retinoblastoma who had lost one eye to advanced disease and had failed all standard attempts to save the remaining eye. The first patient received a single injection of 108 v.p. AdV/TK and the next 3 patients received an initial injection of 109 v.p. followed by either one or 2 injections of 1010 v.p. Each injection was followed by 7 days of intravenous ganciclovir. Results: None of the patients experienced dose-limiting toxicity. The three patients who received 1010 v.p. experienced mild intraocular inflammatory responses that were well controlled with steroid administration. Three patients were enucleated because of advancing disease. One patient has had a complete response and is tumor free with excellent vision 7 months following the completion of therapy. The patients who were enucleated all exhibited tumor necrosis around the injection sites and no viable tumor cells were observed anywhere along the needle track. The patients all had marked decrease in the number of vitreal seeds. Two patients received intratumoral injections of AdV/TK and both exhibited tumor necrosis. All of the patients are currently in excellent health with no toxicity from their therapy. Conclusion: AdV/TK followed by ganciclovir can be safely administered to children with retinoblastoma. Early experience suggests that this form of therapy may have a role in the treatment of retinoblastoma. Based on these early results, permission from the RAC, IRB, and FDA has been received to expand the trial to all retinoblastoma patients who are facing enucleation regardless of previous therapy.

Keywords: 419 gene transfer/gene therapy • 569 retinoblastoma • 307 adenovirus 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.